A Phase 1 interventional study of 14C-bleximenib and bleximenib in Acute Lymphoblastic Leukemia, Acute Leukemias and Acute Myeloid Leukemia, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom — 17 open to participants now, 22 under way, 4 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United Kingdom.
Among the 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom, this one is the 80th largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 in phase 1, and was the 97th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →17 of the 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Australia and 6 more countries
Ages 16+
AstraZeneca · Sites in United Kingdom, United States, Australia and 6 more countries
Ages 12+
Princess Maxima Center for Pediatric Oncology · Sites in United Kingdom, Austria, Belgium and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in United Kingdom, Austria, Belgium and 11 more countries
Ages 1–21
Imperial College London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 43 · Phase 3 24 · Phase 4 2
First in 1992; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 85 across the 83 interventional studies, 178 across the 13 observational. Of the 63 that completed or were terminated, 31 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 4 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
6 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT02443831University College, LondonCARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia | 2026-12-31 |
| NCT04988555Sumitomo Pharma America, Inc.A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | 2027-06-30 |
| NCT05809284University College, LondonDetermining the Mechanisms of Loss of CAR T Cell Persistence | 2027-07-01 |
| NCT04888741University of BirminghamMethods of T Cell Depletion Trial (MoTD) | 2027-08-23 |
Add all 6 to your calendar (.ics) → With an account.
Among the 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of 14C-bleximenib on Cycle 1 Day 1. The recommended Phase 2 dose (RP2D) of bleximenib will start on Cycle 1 Day 2 with non-radiolabeled bleximenib and will continue until the end of Cycle 1 (cycle duration=28 days), with subsequent roll-over for eligible participants to 75276617ALE1001 (NCT04811560) for continued non-radiolabeled bleximenib administration as appropriate.
Drug: 14C-bleximenib · Drug: bleximenib
14C-bleximenib will be administered orally.
Also known as: JNJ-75276617
Non-radiolabeled bleximenib will be administered orally.
Also known as: JNJ-75276617
Percentage of Dose Excreted in Urine (feu)
Total amount excreted into the urine, expressed as a percentage of the administered dose will be reported.
Time frame: Up to Day 28
Percentage of Dose Excreted in Feces (fef)
Total amount excreted into the feces expressed as a percentage of the administered dose will be reported.
Time frame: Up to Day 28
Amount Excreted in Urine (Aeu)
Aeu defined as the total amount of bleximenib and radioactivity excreted into the urine will be reported.
Time frame: Up to Day 28
Amount Excreted in Feces (Aef)
Aef defined as the total amount of bleximenib and radioactivity excreted into the feces will be reported.
Time frame: Up to Day 28
Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)
AUC0-t in whole blood and plasma will be reported.
Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)
Maximum Observed Concentration (Cmax)
Maximum observed concentration in whole blood and plasma will be determined.
Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the study treatment. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Time frame: Up to 58 days
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · innovativemedicine.jnj.com
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Jul 2026, 8 months.
Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's 8 months is below that.
Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Sep 2026 → Jul 2026 and completion Sep 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bleximenib
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Janssen Research & Development, LLC →